Clinical Trials Logo

Clinical Trial Summary

Osteogenesis Imperfecta (OI) is a genetic disorder caused by mutations to the alpha-1 or alpha-2 chain of type I collagen. Clinically, the disorder is characterized by bones that fracture easily, often from little or no apparent trauma. There is no information about Some institutions perform blood pressure monitoring on these patients with a cuff, while other institutions avoid this method due to concern for fracture. Instead, they use alternative forms of monitoring such as an arterial line. These methods come with their own risks, including clotting, decreased perfusion, and pain. In addition, arterial lines require intensive (and more expensive) monitoring in a pediatric intensive care unit due to risk of dislodgement and rapid blood loss. These blood pressure monitoring recommendations for patients with OI do not appear to be based on strong evidence. Anecdotally, some patients and healthcare professionals report hearing about individuals with OI who have suffered fractures from blood pressure cuffs. However, this is not well documented in the medical literature. Regular and accurate blood pressure monitoring is particularly important in the postoperative period, due to blood loss and fluid shifts, as well as utilization of advanced pain management techniques that can potentially impact blood pressure.


Clinical Trial Description

Introduction Osteogenesis Imperfecta (OI) is a genetic disorder caused by mutations to the alpha-1 or alpha-2 chain of type I collagen. There are eight forms of OI, ranging from type I through VIII, however in types V to VIII the symptoms and severity fall within the range of the first four types. Clinically, the disorder is characterized by bones that fracture easily, often from little or no apparent trauma. These patients require special care and handling to minimize risk of fracture, and often undergo multiple surgeries to stabilize fractures and prevent or correct bone deformities. However, specific guidelines and restrictions for care, including clinical and postoperative care, vary between patients and among institutions. Some institutions perform blood pressure monitoring with a circumferential cuff, while other institutions avoid this method due to concern for iatrogenic fracture. Instead, they utilize alternative forms of monitoring such as an arterial line. Currently at Nemours, children and adults with OI have arterial lines placed in the OR for the purpose of BP monitoring. These more invasive methods come with their own risks, including thrombosis, decreased perfusion, and pain. In addition, arterial lines require intensive (and more expensive) monitoring in a pediatric intensive care unit due to risk of dislodgement and rapid blood loss. These blood pressure monitoring recommendations for patients with OI do not appear to be based on strong evidence. Anecdotally, some patients and healthcare professionals report hearing about individuals with OI who have suffered fractures from blood pressure cuffs. However, this is not well supported in the literature. Regular and accurate blood pressure monitoring is particularly important in the postoperative period, due to blood loss and fluid shifts, as well as utilization of advanced pain management techniques that can potentially impact blood pressure. Aim of the study: In this observational study, we intend to evaluate the feasibility of non-invasive cuff blood pressure monitoring in a select group of patients with OI in the inpatient postoperative period. Materials and Methods Following Nemours IRB approval and consent from the parent or legal guardian, fifty children with OI scheduled for lower extremity surgery with subsequent in-hospital admission will be enrolled in the study. Since we performed preformed lower extremity surgeries on thirty patients in each of the past two years, we anticipate the study will take two years to complete. A group of registered nurses would be educated about the study and equipment used, review of appropriate blood pressure cuff size selection, blood pressure monitoring protocol, signs and symptoms of adverse events, and steps to take if an adverse event occurred. Inclusion Criteria: - Patients of all ages with OI who are admitted at our institution to the inpatient, non-ICU setting, in the postoperative period following an orthopedic surgery. - Must be able to tolerate upper extremity blood pressures. - Medical clearance by OI physicians (Kruse, Franzone) after review of fracture history, surgical procedures, x-rays. Exclusion Criteria: - Parent or child refusal, uncooperative child. - History of frequent upper extremity fracture, recent upper extremity fracture (< 8 weeks, or upper extremity fracture that is not yet completely healed). - Thrombocytopenia, admission or transfer to PICU. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04169568
Study type Observational
Source Nemours Children's Clinic
Contact
Status Suspended
Phase
Start date November 15, 2019
Completion date July 15, 2024

See also
  Status Clinical Trial Phase
Completed NCT03557567 - NGS Strategy Effectiveness in Molecular Diagnosis
Active, not recruiting NCT02531087 - Urinary Biomarkers of OI Pathobiology
Completed NCT01713231 - Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta Phase 4
Completed NCT00655681 - Prevention of Post Operative Bone Loss in Children N/A
Recruiting NCT06065111 - Study of Osteogenesis Imperfecta Tendon
Withdrawn NCT03216486 - An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Phase 2
Recruiting NCT06086613 - A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers and Adults and Adolescents With OI Phase 1
Completed NCT04009733 - Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study N/A
Completed NCT04231916 - High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta N/A
Active, not recruiting NCT02814591 - Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
Completed NCT00982124 - An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta Phase 3
Not yet recruiting NCT05612139 - Post-market Observational Study on JTIN Telescopic Nail in Osteogenesis Imperfecta Pediatric Patients
Completed NCT00001305 - Growth Hormone Therapy in Osteogenesis Imperfecta Phase 3
Completed NCT04119388 - Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta N/A
Terminated NCT01679080 - The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta Phase 2
Completed NCT00106028 - Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children Phase 3
Recruiting NCT04152551 - Effects of Bisphosphonates on OI-Related Hearing Loss Phase 4
Completed NCT00705120 - Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation Phase 1
Completed NCT03064074 - Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta Phase 1
Not yet recruiting NCT05258019 - Site Preservation After Tooth Extraction